Quadralynx

Vocal biomarkers to improve Quality of Life

health AI / medtech / digital health (neurodegenerative speech & voice solutions)

Visit website

StageGrant-funded

Raised$983,137

Employees5

LocationSpokane, WA

About

Empowering people living with Parkinson’s disease, Alzheimer’s, and other neurological diseases by offering innovative solutions that improve their quality of life.

Product

Target customers: patients with neurological diseases, clinicians, neurologists

Founders

Gavin La Rowe — Co-Founder & CEO
Mark VanDam — Co-Founder & President

Products

vocal biomarkers platform for neurological diseases

Key features

real-time speech and voice analysisvocal biomarker-based assessmentssolutions to improve quality of life for PD and related conditions

Technologies

speech analyticsbiomarker-based assessmentneurodegenerative disease-focused tech

Target conditions

Parkinson’s diseaseAlzheimer’s diseaseother neurological diseases

Care settings

clinicalhomevirtual

Investors

National Science FoundationSpinout Space

News

Phase II active awardees - NSF SBIR · 2025-08-21T00:00:00.000Z
HSSA expands its scope, invests in startups · 2025-04-24T00:00:00.000Z
HSSA doles out over $4M for bioscience economic development - Life Science Washington Jobs · 2025-04-07T19:38:05.000Z
Lynx secures $27M for consumer-directed health initiatives | MobiHealthNews · 2025-02-10T00:00:00.000Z
Lynx Secures $27M Series A to Simplify Healthcare Payments and Administration · 2025-02-06T16:11:00.000Z
PYMNTS | Doctor’s Orders: Lynx Gets $27M to Close Health and Finance Gap · 2025-02-06T11:30:17.000Z